Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo

Siao Syun Guan, Jungshan Chang, Chun Chia Cheng, Tsai Yueh Luo, Ai Sheng Ho, Chia Chi Wang, Cheng Tien Wu, Shing Hwa Liu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo.

Original languageEnglish
Pages (from-to)4868-4880
Number of pages13
JournalOncotarget
Volume5
Issue number13
Publication statusPublished - 2014

Fingerprint

Micelles
Colorectal Neoplasms
Growth
Neoplasms
Heterografts
Serum
BIBW 2992
In Vitro Techniques
Therapeutic Uses
Stomach Neoplasms
Apoptosis

Keywords

  • Afatinib
  • Colorectal cancer
  • HER2
  • Micelles

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Guan, S. S., Chang, J., Cheng, C. C., Luo, T. Y., Ho, A. S., Wang, C. C., ... Liu, S. H. (2014). Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget, 5(13), 4868-4880.

Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. / Guan, Siao Syun; Chang, Jungshan; Cheng, Chun Chia; Luo, Tsai Yueh; Ho, Ai Sheng; Wang, Chia Chi; Wu, Cheng Tien; Liu, Shing Hwa.

In: Oncotarget, Vol. 5, No. 13, 2014, p. 4868-4880.

Research output: Contribution to journalArticle

Guan, SS, Chang, J, Cheng, CC, Luo, TY, Ho, AS, Wang, CC, Wu, CT & Liu, SH 2014, 'Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo', Oncotarget, vol. 5, no. 13, pp. 4868-4880.
Guan, Siao Syun ; Chang, Jungshan ; Cheng, Chun Chia ; Luo, Tsai Yueh ; Ho, Ai Sheng ; Wang, Chia Chi ; Wu, Cheng Tien ; Liu, Shing Hwa. / Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. In: Oncotarget. 2014 ; Vol. 5, No. 13. pp. 4868-4880.
@article{01bb6d7a4d674b9ebc01117ad921b27b,
title = "Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo",
abstract = "Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo.",
keywords = "Afatinib, Colorectal cancer, HER2, Micelles",
author = "Guan, {Siao Syun} and Jungshan Chang and Cheng, {Chun Chia} and Luo, {Tsai Yueh} and Ho, {Ai Sheng} and Wang, {Chia Chi} and Wu, {Cheng Tien} and Liu, {Shing Hwa}",
year = "2014",
language = "English",
volume = "5",
pages = "4868--4880",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "13",

}

TY - JOUR

T1 - Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo

AU - Guan, Siao Syun

AU - Chang, Jungshan

AU - Cheng, Chun Chia

AU - Luo, Tsai Yueh

AU - Ho, Ai Sheng

AU - Wang, Chia Chi

AU - Wu, Cheng Tien

AU - Liu, Shing Hwa

PY - 2014

Y1 - 2014

N2 - Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo.

AB - Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo.

KW - Afatinib

KW - Colorectal cancer

KW - HER2

KW - Micelles

UR - http://www.scopus.com/inward/record.url?scp=84904977776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904977776&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 4868

EP - 4880

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -